These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 16339215)

  • 1. Gain-of-function haplotypes in the vesicular monoamine transporter promoter are protective for Parkinson disease in women.
    Glatt CE; Wahner AD; White DJ; Ruiz-Linares A; Ritz B
    Hum Mol Genet; 2006 Jan; 15(2):299-305. PubMed ID: 16339215
    [TBL] [Abstract][Full Text] [Related]  

  • 2. hVMAT2: A Target of Individualized Medication for Parkinson's Disease.
    Xiong N; Li N; Martin E; Yu J; Li J; Liu J; Lee DY; Isacson O; Vance J; Qing H; Wang T; Lin Z
    Neurotherapeutics; 2016 Jul; 13(3):623-34. PubMed ID: 27137201
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SLC18A2 promoter haplotypes and identification of a novel protective factor against alcoholism.
    Lin Z; Walther D; Yu XY; Li S; Drgon T; Uhl GR
    Hum Mol Genet; 2005 May; 14(10):1393-404. PubMed ID: 15829504
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of vesicular monoamine transporter 2 polymorphisms in Parkinson's disease.
    Brighina L; Riva C; Bertola F; Saracchi E; Fermi S; Goldwurm S; Ferrarese C
    Neurobiol Aging; 2013 Jun; 34(6):1712.e9-13. PubMed ID: 23369548
    [TBL] [Abstract][Full Text] [Related]  

  • 5. VMAT2 and Parkinson's disease: harnessing the dopamine vesicle.
    Lohr KM; Miller GW
    Expert Rev Neurother; 2014 Oct; 14(10):1115-7. PubMed ID: 25220836
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vesicular monoamine transporter 2 mediates fear behavior in mice.
    Branco RC; Burkett JP; Black CA; Winokur E; Ellsworth W; Dhamsania RK; Lohr KM; Schroeder JP; Weinshenker D; Jovanovic T; Miller GW
    Genes Brain Behav; 2020 Jun; 19(5):e12634. PubMed ID: 31898856
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association study of the vesicular monoamine transporter gene SLC18A2 with tardive dyskinesia.
    Zai CC; Tiwari AK; Mazzoco M; de Luca V; Müller DJ; Shaikh SA; Lohoff FW; Freeman N; Voineskos AN; Potkin SG; Lieberman JA; Meltzer HY; Remington G; Kennedy JL
    J Psychiatr Res; 2013 Nov; 47(11):1760-5. PubMed ID: 24018103
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vesicular monoamine transporter 2 mRNA levels are reduced in platelets from patients with Parkinson's disease.
    Sala G; Brighina L; Saracchi E; Fermi S; Riva C; Carrozza V; Pirovano M; Ferrarese C
    J Neural Transm (Vienna); 2010 Sep; 117(9):1093-8. PubMed ID: 20665056
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A fluorescent-based assay for live cell, spatially resolved assessment of vesicular monoamine transporter 2-mediated neurotransmitter transport.
    Bernstein AI; Stout KA; Miller GW
    J Neurosci Methods; 2012 Aug; 209(2):357-66. PubMed ID: 22698664
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High regulatability favors genetic selection in SLC18A2, a vesicular monoamine transporter essential for life.
    Lin Z; Zhao Y; Chung CY; Zhou Y; Xiong N; Glatt CE; Isacson O
    FASEB J; 2010 Jul; 24(7):2191-200. PubMed ID: 20181938
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of a gastrin response element in the vesicular monoamine transporter type 2 promoter and requirement of 20 S proteasome subunits for transcriptional activity.
    Catlow K; Ashurst HL; Varro A; Dimaline R
    J Biol Chem; 2007 Jun; 282(23):17069-77. PubMed ID: 17442673
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DJ-1 protects against dopamine toxicity: implications for Parkinson's disease and aging.
    Lev N; Barhum Y; Pilosof NS; Ickowicz D; Cohen HY; Melamed E; Offen D
    J Gerontol A Biol Sci Med Sci; 2013 Mar; 68(3):215-25. PubMed ID: 22887838
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Variations in the vesicular monoamine transporter 1 gene (VMAT1/SLC18A1) are associated with bipolar i disorder.
    Lohoff FW; Dahl JP; Ferraro TN; Arnold SE; Gallinat J; Sander T; Berrettini WH
    Neuropsychopharmacology; 2006 Dec; 31(12):2739-47. PubMed ID: 16936705
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The promoter region of the MDR1 gene is largely invariant, but different single nucleotide polymorphism haplotypes affect MDR1 promoter activity differently in different cell lines.
    Wang B; Ngoi S; Wang J; Chong SS; Lee CG
    Mol Pharmacol; 2006 Jul; 70(1):267-76. PubMed ID: 16608921
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Involvement of vesicular monoamine transporter in attention deficit hyperactivity disorder].
    Lorenzo-Sanz G; Sánchez-Herranz A
    Rev Neurol; 2011 Mar; 52 Suppl 1():S103-8. PubMed ID: 21365590
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decreased vesicular monoamine transporter 2 (VMAT2) and dopamine transporter (DAT) function in knockout mice affects aging of dopaminergic systems.
    Hall FS; Itokawa K; Schmitt A; Moessner R; Sora I; Lesch KP; Uhl GR
    Neuropharmacology; 2014 Jan; 76 Pt A(0 0):146-55. PubMed ID: 23978383
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transcriptional activation of vesicular monoamine transporter 2 in the pre-B cell line Ea3.123.
    Watson F; Deavall DG; Macro JA; Kiernan R; Dimaline R
    Biochem J; 1999 Jan; 337 ( Pt 2)(Pt 2):193-9. PubMed ID: 9882615
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased vesicular monoamine transporter enhances dopamine release and opposes Parkinson disease-related neurodegeneration in vivo.
    Lohr KM; Bernstein AI; Stout KA; Dunn AR; Lazo CR; Alter SP; Wang M; Li Y; Fan X; Hess EJ; Yi H; Vecchio LM; Goldstein DS; Guillot TS; Salahpour A; Miller GW
    Proc Natl Acad Sci U S A; 2014 Jul; 111(27):9977-82. PubMed ID: 24979780
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased vulnerability to L-DOPA toxicity in dopaminergic neurons From VMAT2 heterozygote knockout mice.
    Kariya S; Takahashi N; Hirano M; Ueno S
    J Mol Neurosci; 2005; 27(3):277-79. PubMed ID: 16280597
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stimulation of vesicular monoamine transporter 2 activity by DJ-1 in SH-SY5Y cells.
    Ishikawa S; Tanaka Y; Takahashi-Niki K; Niki T; Ariga H; Iguchi-Ariga SM
    Biochem Biophys Res Commun; 2012 May; 421(4):813-8. PubMed ID: 22554508
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.